Notice2022-26057
Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON® (Mafenide Acetate, USP) Powder for 5% Topical Solution
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 30, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is withdrawing approval of new drug application (NDA) 019832 for SULFAMYLON[supreg] (Mafenide Acetate, USP) Powder for 5% Topical Solution, held by Mylan Institutional, Inc., a Viatris company (Mylan). Mylan has voluntarily requested withdrawal of this application and has waived its opportunity for a hearing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 229 (Wednesday, November 30, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 229 (Wednesday, November 30, 2022)]
[Notices]
[Page 73561]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-26057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-2855]
Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug
Application for SULFAMYLON[supreg] (Mafenide Acetate, USP) Powder for
5% Topical Solution
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval
of new drug application (NDA) 019832 for SULFAMYLON[supreg] (Mafenide
Acetate, USP) Powder for 5% Topical Solution, held by Mylan
Institutional, Inc., a Viatris company (Mylan). Mylan has voluntarily
requested withdrawal of this application and has waived its opportunity
for a hearing.
DATES: Applicable November 30, 2022.
FOR FURTHER INFORMATION CONTACT: Kristiana Brugger, Office of
Regulatory Policy, Center for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6262,
Silver Spring, MD 20993, 301-796-3601.
SUPPLEMENTARY INFORMATION: On June 5, 1998, the Food and Drug
Administration (FDA) approved NDA 019832 for SULFAMYLON[supreg]
(Mafenide Acetate, USP) Powder for 5% Topical Solution, under the
Agency's accelerated approval regulations (see generally 21 CFR subpart
H). It was approved for ``for use as an adjunctive topical
antimicrobial agent to control bacterial infection when used under
moist dressings over meshed autografts on excised burn wounds.''
NDA 019832's accelerated approval was ``subject to the requirement
that the applicant study the drug further, to verify and describe its
clinical benefit, where there is uncertainty as to the relation of the
surrogate endpoint to clinical benefit, or of the observed clinical
benefit to ultimate outcome'' (21 CFR 314.510). To date, however, Mylan
has not completed the required confirmatory study. Mylan acknowledged
in its December 10, 2021, letter requesting withdrawal of approval that
a successful confirmatory study was necessary to fulfill the
accelerated approval requirements, but stated that conducting such a
study is not feasible. Mylan thus requested that NDA 019832 be
withdrawn under 21 CFR 314.150(d), and waived its right to a hearing.
Thus, for the reasons discussed above, under 21 CFR 314.150(d),
approval of NDA 019832 for SULFAMYLON[supreg] (Mafenide Acetate, USP)
Powder for 5% Topical Solution, and all amendments and supplements
thereto, is withdrawn. Distribution of SULFAMYLON[supreg] (Mafenide
Acetate, USP) Powder for 5% Topical Solution in interstate commerce
without an approved application is illegal and subject to regulatory
action (see sections 505(a) and 301(d) of the FD&C Act (21 U.S.C.
355(a) and 331(d)).
Dated: November 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-26057 Filed 11-29-22; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on November 30, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.